ClinicalTrials.gg
CompletedNCT02993406CLEAR OutcomesUpdated Jan 3, 2024Results posted

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

A Phase 3 interventional study of Bempedoic acid 180 mg tablet and Matching placebo tablet in Cardiovascular Diseases and Statin Adverse Reaction, sponsored by Esperion Therapeutics, Inc.. Completed at 1,332 sites in 32 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13,970
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.

02

Conditions studied

  • Cardiovascular Diseases
  • Statin Adverse Reaction
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 13,970 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 85 years
  • History of, or at high risk for, cardiovascular disease (CVD) including coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease, or at high risk for a cardiovascular event
  • Participant-reported SI due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued resulting in an inability to tolerate:

    • 2 or more statins at any dose, or
    • 1 statin at any dose and unwilling to attempt a second statin or advised by a physician to not attempt a second statin.

Please note that participants currently tolerating very low dose statin therapy (an average daily dose of rosuvastatin \<5 mg, atorvastatin \<10 mg, simvastatin \<10 mg, lovastatin \<20 mg, pravastatin \<40 mg, fluvastatin \<40 mg, or pitavastatin \<2 mg) are considered to be intolerant to that low dose statin. Patients may continue taking very low dose statin therapy throughout the study provided that it is stable (used for at least 4 weeks prior to screening) and well tolerated.

  • Written confirmation by both participant and investigator that the participant is statin intolerant as defined above, aware of the benefit of statin use to reduce the risk of MACE including death, and also aware that many other participants who are unable to tolerate a statin are able to tolerate a different statin or dose.
  • Men and nonpregnant, nonlactating women
  • Fasting blood LDL-cholesterol ≥ 100 (2.6 mmol/L) at screening

Exclusion criteria

Exclusion Criteria:

  • Fasting blood triglycerides greater than 500 mg/dL (5.6 mmol/L) at screening
  • Recent (within 90 days of screening) history of major cardiovascular events, (TIA), or unstable or symptomatic cardiac arrhythmia
  • History of severe heart failure
  • Uncontrolled hypertension or uncontrolled diabetes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
13,970 participants (actual)

Study arms

  • Experimental
    Bempedoic Acid 180 mg

    Bempedoic acid 180 mg tablet taken orally, once daily.

    Drug: Bempedoic acid 180 mg tablet

  • Placebo comparator
    Placebo Comparator

    Matching placebo tablet taken orally, once daily

    Drug: Matching placebo tablet

Interventions

  • Patients take bempedoic acid 180 mg tablet orally once daily

    Also known as: ETC-1002

  • DrugMatching placebo tablet

    Patients take matching placebo tablet orally once daily

    Also known as: placebo comparator

06

What researchers measure

Primary outcomes

  1. Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)

    The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.

    Time frame: Up to 68 months

Secondary outcomes

  1. Number of Participants With First Occurrence of Three Component MACE

    The first key secondary end point was a three-component MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

    Time frame: Up to 68 months

  2. Number of Participants With First Occurrence of Myocardial Infarction

    Number of participants with time to first occurrence of fatal and non-fatal myocardial infarction are presented.

    Time frame: Up to 68 months

  3. Number of Participants With Time to First Occurrence of Coronary Revascularization

    Number of participants with time to first occurrence of coronary revascularization are presented.

    Time frame: Up to 68 months

  4. Number of Participants With Time to First Occurrence of Stroke

    Number of participants with time to first occurrence of fatal and non-fatal stroke.

    Time frame: Up to 68 months

  5. Number of Participants With Time to Cardiovascular Death

    Number of participants with time to cardiovascular death are presented.

    Time frame: Up to 68 months

  6. Number of Participants With Time to All-cause Mortality

    All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.

    Time frame: Up to 68 months

07

Results

Posted Jan 3, 2024

Participant flow

This was a randomized, double-blind, placebo-controlled, parallel-group study that assessed the occurrence of major adverse cardiovascular event (MACE) in participants with, or at high risk for, cardiovascular disease (CVD) who were unable to tolerate statin therapy.

Participant flow — Overall Study
MilestoneBempedoic Acid 180 Milligrams (mg)Placebo Comparator
Started69926978
Completed66976620
Not completed295358
Withdrew: Withdrawal by subject170196
Withdrew: Physician decision35
Withdrew: Lost to follow-up1213
Withdrew: Unclassifiable response105139
Withdrew: Administrative decision10
Withdrew: Sponsor decision45

Outcome measures

PrimaryNumber of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)

The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.

Time frame:
Up to 68 months
Reported as:
Count of participants · Participants
Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)
ParticipantsBempedoic Acid 180 mgPlacebo Comparator
Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)819927
Statistical analysis
  • Bempedoic Acid 180 mg vs Placebo Comparator · Log Rank · p = 0.004 · Hazard ratio (hr): 0.87 · 95% CI 0.79 to 0.96
SecondaryNumber of Participants With First Occurrence of Three Component MACE

The first key secondary end point was a three-component MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

Time frame:
Up to 68 months
Reported as:
Count of participants · Participants
Number of Participants With First Occurrence of Three Component MACE
ParticipantsBempedoic Acid 180 mgPlacebo Comparator
Number of Participants With First Occurrence of Three Component MACE575663
Statistical analysis
  • Bempedoic Acid 180 mg vs Placebo Comparator · Log Rank · p = 0.0058 · Hazard ratio (hr): 0.85 · 95% CI 0.76 to 0.96
SecondaryNumber of Participants With First Occurrence of Myocardial Infarction

Number of participants with time to first occurrence of fatal and non-fatal myocardial infarction are presented.

Time frame:
Up to 68 months
Reported as:
Count of participants · Participants
Number of Participants With First Occurrence of Myocardial Infarction
ParticipantsBempedoic Acid 180 mgPlacebo Comparator
Number of Participants With First Occurrence of Myocardial Infarction261334
Statistical analysis
  • Bempedoic Acid 180 mg vs Placebo Comparator · Log Rank · p = 0.0016 · Hazard ratio (hr): 0.77 · 95% CI 0.66 to 0.91
SecondaryNumber of Participants With Time to First Occurrence of Coronary Revascularization

Number of participants with time to first occurrence of coronary revascularization are presented.

Time frame:
Up to 68 months
Reported as:
Count of participants · Participants
Number of Participants With Time to First Occurrence of Coronary Revascularization
ParticipantsBempedoic Acid 180 mgPlacebo Comparator
Number of Participants With Time to First Occurrence of Coronary Revascularization435529
Statistical analysis
  • Bempedoic Acid 180 mg vs Placebo Comparator · Log Rank · p = 0.0013 · Hazard ratio (hr): 0.81 · 95% CI 0.72 to 0.92
SecondaryNumber of Participants With Time to First Occurrence of Stroke

Number of participants with time to first occurrence of fatal and non-fatal stroke.

Time frame:
Up to 68 months
Reported as:
Count of participants · Participants
Number of Participants With Time to First Occurrence of Stroke
ParticipantsBempedoic Acid 180 mgPlacebo Comparator
Number of Participants With Time to First Occurrence of Stroke135158
Statistical analysis
  • Bempedoic Acid 180 mg vs Placebo Comparator · Log Rank · p = 0.1593 · Hazard ratio (hr): 0.85 · 95% CI 0.67 to 1.07
SecondaryNumber of Participants With Time to Cardiovascular Death

Number of participants with time to cardiovascular death are presented.

Time frame:
Up to 68 months
Reported as:
Count of participants · Participants
Number of Participants With Time to Cardiovascular Death
ParticipantsBempedoic Acid 180 mgPlacebo Comparator
Number of Participants With Time to Cardiovascular Death269257
Statistical analysis
  • Bempedoic Acid 180 mg vs Placebo Comparator · Log Rank · p = 0.6227 · Hazard ratio (hr): 1.04 · 95% CI 0.88 to 1.24
SecondaryNumber of Participants With Time to All-cause Mortality

All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.

Time frame:
Up to 68 months
Reported as:
Count of participants · Participants
Number of Participants With Time to All-cause Mortality
ParticipantsBempedoic Acid 180 mgPlacebo Comparator
Number of Participants With Time to All-cause Mortality434420
Statistical analysis
  • Bempedoic Acid 180 mg vs Placebo Comparator · Log Rank · p = 0.6608 · Hazard ratio (hr): 1.03 · 95% CI 0.90 to 1.18

Adverse events

Collected over Up to 68 months. Serious adverse events (SAEs) and non-SAEs were collected from Safety Population. The Safety Population comprises of all randomized participants who received at least 1 dose of study medication (investigational product). Deaths were endpoints and not reported as SAEs. Negatively adjudicated non- fatal MACE events were reported as SAEs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bempedoic Acid 180 mg437/7,001 (6.2%)1,767/7,001 (25.2%)5,805/7,001 (82.9%)
Placebo Comparator420/6,964 (6%)1,733/6,964 (24.9%)5,490/6,964 (78.8%)
Most frequent serious events
Showing 10 of 1,195
Most frequent serious events
EventBempedoic Acid 180 mgPlacebo Comparator
Atrial fibrillationCardiac disorders81/700195/6964
COVID-19 pneumoniaInfections and infestations84/700190/6964
PneumoniaInfections and infestations84/700181/6964
Angina pectorisCardiac disorders56/700182/6964
COVID-19Infections and infestations56/700175/6964
OsteoarthritisMusculoskeletal and connective tissue disorders71/700169/6964
Non-cardiac chest painGeneral disorders50/700157/6964
Angina unstableCardiac disorders56/700153/6964
Transient ischaemic attackNervous system disorders41/700136/6964
Cardiac failure congestiveCardiac disorders39/700137/6964
Most frequent other events
Showing 10 of 11
Most frequent other events
EventBempedoic Acid 180 mgPlacebo Comparator
HypertensionVascular disorders747/7001804/6964
COVID-19Infections and infestations731/7001801/6964
HyperuricaemiaMetabolism and nutrition disorders763/7001393/6964
ArthralgiaMusculoskeletal and connective tissue disorders548/7001554/6964
Urinary tract infectionInfections and infestations539/7001515/6964
HeadacheNervous system disorders479/7001493/6964
MyalgiaMusculoskeletal and connective tissue disorders392/7001470/6964
Diabetes mellitusMetabolism and nutrition disorders458/7001435/6964
Back painMusculoskeletal and connective tissue disorders404/7001450/6964
Blood uric acid increasedInvestigations393/7001186/6964

Baseline characteristics

Intention-to-Treat Population is defined as all randomized participants.

Age, Continuous
Age, Continuous(Years)Bempedoic Acid 180 mgPlacebo ComparatorTotal
Mean65.5 ± 9.065.5 ± 8.965.5 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Bempedoic Acid 180 mgPlacebo ComparatorTotal
Female336133796740
Male363135997230
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bempedoic Acid 180 mgPlacebo ComparatorTotal
Hispanic or Latino119011432333
Not Hispanic or Latino5802583511637
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bempedoic Acid 180 mgPlacebo ComparatorTotal
American Indian or Alaska Native240247487
Asian130136266
Native Hawaiian or Other Pacific Islander201737
Black or African American156172328
White6397633512732
More than one race4870118
Unknown or Not Reported112
08

Study locations

1,332 sites
  • Birmingham, Alabama 35211, United States
  • Birmingham, Alabama 35235, United States
  • Huntsville, Alabama 35802, United States
  • Mobile, Alabama 36608, United States
  • Mobile, Alabama 36617, United States
  • Pell City, Alabama 35125, United States
  • Tuscumbia, Alabama 35674, United States
  • Chandler, Arizona 85224, United States
  • Cottonwood, Arizona 86326, United States
  • Fountain Hills, Arizona 85268, United States
  • Gilbert, Arizona 85295, United States
  • Glendale, Arizona 85306, United States
  • Glendale, Arizona 85308, United States
  • Mesa, Arizona 85206, United States
  • Phoenix, Arizona 85020, United States
  • Phoenix, Arizona 85050, United States
  • Tucson, Arizona 85712, United States
  • Tucson, Arizona 85741, United States
  • Beverly Hills, California 90211, United States
  • Carlsbad, California 92008, United States
  • Huntington Beach, California 92648-1717, United States
  • Lincoln, California 95648, United States
  • Long Beach, California 90806, United States
  • Long Beach, California 90807, United States
  • Northridge, California 91324, United States
  • Oceanside, California 92056, United States
  • Rancho Cucamonga, California 91730, United States
  • San Diego, California 92108, United States
  • Santa Ana, California 92705, United States
  • Santa Rosa, California 95405, United States
  • Torrance, California 90509, United States
  • Vista, California 92083, United States
  • Aurora, Colorado 80012, United States
  • Colorado Springs, Colorado 80909, United States
  • Colorado Springs, Colorado 80922, United States
  • Golden, Colorado 80401, United States
  • Littleton, Colorado 80120, United States
  • Loveland, Colorado 80538, United States
  • Hamden, Connecticut 06517, United States
  • Hartford, Connecticut 06102, United States
  • North Haven, Connecticut 06473, United States
  • Stamford, Connecticut 06905, United States
  • Boca Raton, Florida 33434, United States
  • Boynton Beach, Florida 33435, United States
  • Boynton Beach, Florida 33472, United States
  • Bradenton, Florida 34209, United States
  • Clearwater, Florida 33756, United States
  • Crystal River, Florida 34429, United States
  • Fleming Island, Florida 32003, United States
  • Fort Lauderdale, Florida 33008, United States
  • Fort Lauderdale, Florida 33308, United States
  • Greenacres City, Florida 33467, United States
  • Hialeah, Florida 33010, United States
  • Hialeah, Florida 33012, United States
  • Inverness, Florida 34452, United States
  • Jacksonville, Florida 32205, United States
  • Jacksonville, Florida 32216, United States
  • Jacksonville, Florida 32277, United States
  • Jupiter, Florida 33458, United States
  • Lake Worth, Florida 33461, United States
  • Largo, Florida 33770, United States
  • Largo, Florida 33777, United States
  • Melbourne, Florida 32934, United States
  • Miami Lakes, Florida 33016, United States
  • Miami, Florida 33125, United States
  • Miami, Florida 33126, United States
  • Miami, Florida 33133, United States
  • Miami, Florida 33144, United States
  • Miami, Florida 33165, United States
  • Miami, Florida 33172, United States
  • Miami, Florida 33173, United States
  • Miami, Florida 33175, United States
  • Miami, Florida 33186, United States
  • Naples, Florida 34102, United States
  • New Port Richey, Florida 34655, United States
  • North Miami Beach, Florida 33162, United States
  • Ocala, Florida 34471, United States
  • Orlando, Florida 32825, United States
  • Ormond Beach, Florida 32174, United States
  • Pembroke Pines, Florida 33025, United States
  • Pembroke Pines, Florida 33026, United States
  • Pembroke Pines, Florida 33027, United States
  • Pinellas Park, Florida 33781, United States
  • Ponte Vedra, Florida 32081, United States
  • Port Charlotte, Florida 33952, United States
  • Safety Harbor, Florida 34695, United States
  • Saint Petersburg, Florida 33713, United States
  • Tampa, Florida 33624, United States
  • Wellington, Florida 33449, United States
  • Atlanta, Georgia 30322, United States
  • Columbus, Georgia 31904, United States
  • Covington, Georgia 30014, United States
  • Cumming, Georgia 30041, United States
  • Dunwoody, Georgia 30338, United States
  • Gainesville, Georgia 30501, United States
  • Macon, Georgia 31201, United States
  • Savannah, Georgia 31406, United States
  • Tucker, Georgia 30084, United States
  • Woodstock, Georgia 30189, United States
  • Meridian, Idaho 83646, United States

Showing the first 100 of 1,332 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep. 2016 Oct;18(10):61. doi: 10.1007/s11883-016-0611-4. PubMed 27663902 ↗
  • Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun;10(3):556-67. doi: 10.1016/j.jacl.2015.12.025. Epub 2016 Jan 6. PubMed 27206943 ↗
  • Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May-Jun;9(3):295-304. doi: 10.1016/j.jacl.2015.03.003. Epub 2015 Mar 19. PubMed 26073387 ↗
  • Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, Libby P, Moriarty PM, Plutzky J, Ray KK, Thompson PD, Sasiela W, Mason D, McCluskey J, Davey D, Wolski K, Nissen SE. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021 May;235:104-112. doi: 10.1016/j.ahj.2020.10.060. Epub 2020 Oct 24. PubMed 33470195 ↗
  • Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. PubMed 36876740 ↗
  • Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023 Jul 11;330(2):131-140. doi: 10.1001/jama.2023.9696. PubMed 37354546 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Nov 2022, 70 months.

Results were first posted in Jan 2024, 1 year 1 month after primary completion.

Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 70 months is above that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2016
First posted
Dec 15, 2016
StartActual
Dec 22, 2016
Primary completionActual
Nov 7, 2022
CompletionActual
Nov 7, 2022
Results first posted
Jan 3, 2024
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02993406
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Dec 22, 2016
Primary completion
Nov 7, 2022
Completion
Nov 7, 2022
Results posted
Jan 3, 2024
Last update
Jan 3, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion